Christopher Ogden serves as Executive at CytomX Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Christopher Ogden has executed 11 insider transactions totaling $12.4K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 2, 2026 involved receiving (via award) 325,000 shares valued at $0.
Christopher Ogden currently holds 325,000 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Ogden has been a net seller of CTMX stock. They have purchased $0 and sold $12.4K worth of shares.
Christopher Ogden's most recent insider trade was on Feb 2, 2026, when they sold 325,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Aug 20, 2024 | CTMX | $2.4K | Sale | 1,984 | $1.23 | Discretionary |
| Aug 20, 2024 | CTMX | $0 | Option Exercise | 6,875 | $N/A | Discretionary |
| Jun 12, 2024 | CTMX | $0 | Award | 17,500 | $N/A | Discretionary |
| Mar 19, 2024 | CTMX | $6.2K | Sale | 2,971 | $2.09 | Discretionary |
| Jan 18, 2024 | CTMX | $0 | Award | 40,000 | $N/A | Discretionary |
| Dec 20, 2023 | CTMX | $2.7K | Sale | 1,990 | $1.38 | Discretionary |
| Dec 17, 2023 | CTMX | $0 | Option Exercise | 6,875 | $N/A | Discretionary |
| Mar 16, 2023 | CTMX | $1.0K | Sale | 516 | $1.98 | Discretionary |
| Feb 2, 2023 | CTMX | $0 | Award | 25,000 | $N/A | Discretionary |